AIRLINK 74.95 Increased By ▲ 1.25 (1.7%)
BOP 4.92 Increased By ▲ 0.02 (0.41%)
CNERGY 4.44 Decreased By ▼ -0.08 (-1.77%)
DFML 42.90 Decreased By ▼ -1.98 (-4.41%)
DGKC 84.74 Decreased By ▼ -0.76 (-0.89%)
FCCL 21.17 Decreased By ▼ -0.23 (-1.07%)
FFBL 32.35 Decreased By ▼ -0.16 (-0.49%)
FFL 9.50 Decreased By ▼ -0.09 (-0.94%)
GGL 10.11 Decreased By ▼ -0.16 (-1.56%)
HASCOL 7.02 Decreased By ▼ -0.11 (-1.54%)
HBL 114.50 Decreased By ▼ -0.20 (-0.17%)
HUBC 138.50 Decreased By ▼ -0.60 (-0.43%)
HUMNL 12.08 Decreased By ▼ -0.34 (-2.74%)
KEL 4.97 Decreased By ▼ -0.06 (-1.19%)
KOSM 4.42 Decreased By ▼ -0.03 (-0.67%)
MLCF 37.00 Decreased By ▼ -0.60 (-1.6%)
OGDC 134.25 Decreased By ▼ -2.55 (-1.86%)
PAEL 25.28 Decreased By ▼ -0.11 (-0.43%)
PIBTL 6.64 Decreased By ▼ -0.05 (-0.75%)
PPL 119.10 Decreased By ▼ -1.90 (-1.57%)
PRL 26.38 Decreased By ▼ -0.21 (-0.79%)
PTC 13.95 Decreased By ▼ -0.15 (-1.06%)
SEARL 56.66 Decreased By ▼ -0.64 (-1.12%)
SNGP 66.80 Decreased By ▼ -1.20 (-1.76%)
SSGC 10.35 Decreased By ▼ -0.07 (-0.67%)
TELE 8.31 Decreased By ▼ -0.14 (-1.66%)
TPLP 10.91 Decreased By ▼ -0.07 (-0.64%)
TRG 62.86 Decreased By ▼ -0.48 (-0.76%)
UNITY 26.92 Decreased By ▼ -0.13 (-0.48%)
WTL 1.35 Decreased By ▼ -0.03 (-2.17%)
BR100 7,896 Decreased By -44.4 (-0.56%)
BR30 25,360 Decreased By -288.1 (-1.12%)
KSE100 75,154 Decreased By -363 (-0.48%)
KSE30 24,136 Decreased By -142 (-0.58%)

Pakistani pharmaceutical company Abbott Laboratories suffered losses to the tune of Rs579.85 million in the second quarter which ended June, 30, 2023, as compared to a profit of Rs338.2 million in same period last year (SPLY).

The company, in its financial statements provided to the Pakistan Stock Exchange (PSX) on Wednesday, attributed the losses to a rise in production cost amid ongoing rupee devaluation and rise in inflation.

The company posted a loss per share of Rs5.93 in Q2 2023, as compared to an earning per share of Rs3.45 per share in SPLY.

Sales for the quarter clocked in at Rs13.44 billion, an increase of 4% over the SPLY.

“Pharmaceutical sales increased by 12% whereas sales for nutrition decreased by 18% mainly on account of lower volumes following restrained demand due to inflationary pressures,” said Abbott.

However, despite higher sales the pharmaceutical’s gross profit margin declined to 19% in 2QCY23 from 34% during the SPLY.

“This is mainly due to increase in product costs on account of rupee devaluation and inflation,” stated the company, as the cost of sales increased to Rs10.84 billion from Rs8.53 billion in SPLY.

Operating expenses increased by 16% over the same period last year mainly due to inflation. Other charges decreased by 82% over the same period last year due to impact of exchange losses in 2QCY22.

Abbott’s tax charge for the quarter decreased by 44% to Rs971.72 million as compared to 1.729 billion in SPLY. “This is in line with lower profitability and impact of prior year super tax levy in 2QCY22,” said the pharmaceutical.

Abbott stated it continues to face challenges of inflation and rupee devaluation.

It urged the Drug Regulatory Authority of Pakistan to conduct necessary pricing review and adjustments.

“As a long-term measure, the Authority may consider introducing automatic mechanism and policy to offset the impact of devaluation,” it suggested.

Comments

Comments are closed.

Tulukan Mairandi Aug 30, 2023 04:03pm
Time to shut shop and sell to Xibott of china
thumb_up Recommended (0)
TheActualTruth Aug 30, 2023 09:26pm
No Comments
thumb_up Recommended (0)
Saleem Munshi Aug 31, 2023 01:20pm
And the show must go on at whatever cost it may be to all except the puppet masters.
thumb_up Recommended (0)